Posts tagged PMN310
Mackie starts Promis at speculative buy

Mackie Research Capital initiated coverage of Promis Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents, saying the company has a promising new path to target Alzheimer’s disease (AD). The stock closed at 25 cents on Sept. 18.

Read More